headache migraine
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: Migraine according to the IHS classification ICHD III (2013): repeated attacks of moderate to intense headache, usually unilateral, throbbing headache with nausea and/or vomiting, duration of the headache attack between 4 and 72 hours, two or more attacks per month. Increasing with physical activity such as climbing stairs. Photofobia or phonofobia. Tensiontype headache (TTH) ICHD III (2013) that can be distinguished by the participant. Migraine with aura symptoms such as neck pain and additional presence of vision changes , tingling or numbness in lips, face, or hand (onesided), one-sided muscle weakness, or impaired speech. Migraine more than 1 year present and participants who are stable on prophylactic medication. Age: between 18 years 65 years Participant is able to fill in questionnaires (understand Dutch language)
Exclusion criteria
Exclusion criteria: Exclusion criteria are suspected malignancy, pregnancy, cerebrovascular disease, degenerative central nervous system diseases, medication-overuse headache, a current diagnosis of depression or other severe psychiatric disease, rheumatoid arthritis, serious or systemic infection, fever, or change in medication for migraine within three months before the study, and having received MT treatment for migraine up to three months prior to the start of the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary outcome of the study is the number of migraine days, administrated by the participant in a headache diary during the four weeks prior to the follow-up assessments (Tfelt-Hansen 2012). A migraine day is defined as a day with migraine characteristics according to the IHS classification ICDH III for longer than four hours, or a headache that resolves with the intake of triptans or ergotamine within two hours of intake. | — |
Secondary
| Measure | Time frame |
|---|---|
| All of the secondary outcome measures will be assessed at 12, 26 and 52 weeks follow-up assessments. The secondary outcome measures are: 1. Number of migraine attacks per four weeks, administrated in a headache diary during the four weeks before follow-up measurements (Tfelt-Hansen 2012). Migraine attacks will be considered as separate attacks if 48 hours without headache is reported in the headache diary between migraine days. 2. Pain intensity of migraine, assessed on an 11 point numerical rating scale (0 = no pain, 10 = most severe pain) (Williamson 2005). 3. Neck pain intensity, assessed on an 11 point numerical rating scale (0 = no pain, 10 = most severe pain). 4. Medication use in number of doses per 4 weeks of simple analgesics (e.g., paracetamol), NSAIDs, acute migraine medication (triptans and ergotamines) or prophylactic medication. Change of medication will be administrated and reported. 5. Responder rate will be measured by the number of migraine days before vs. after treatment, dichotomized into *50% reduction or not (Tfelt-Hansen 2012). 6. Disability, assessed by the HIT-6 questionnaire. The HIT-6 consists of 6 questions measuring pain intensity, social functioning, role functioning, vitality, cognitive functioning and psychological distress on a 5 point ordinal rating scale (never, to always). Internal consistency is considered high (Cronbach's alpha 0.82 to 0.90), and test-retest reliability is fair (ICC 0.77) (Yang 2011). The Dutch version of the HIT-6 questionnaire has shown to be a valid and reliable tool to measure the impact of migraine (Martin 2004). 7. The endurance of the neck flexor muscles will be scored as the number of seconds the participant can raise his head from the table when lying in supine position as described by Harris et al. (2005). 8. Cutaneous allodynia (CA) will be evaluated with the 12 item allodynia symptom checklist (ASC-12). This questionnaire consists of 12 questions about cutaneous hypersensitivity in the cervical ceph | — |
Countries
Netherlands